Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects

被引:29
作者
Spina, E [1 ]
Avenoso, A [1 ]
Campo, GM [1 ]
Scordo, MG [1 ]
Caputi, AP [1 ]
Perucca, E [1 ]
机构
[1] UNIV PAVIA,CLIN PHARMACOL UNIT,I-27100 PAVIA,ITALY
关键词
ketoconazole; imipramine; desipramine; CYP3A4; CYP2D6; drug interaction;
D O I
10.1046/j.1365-2125.1997.00539.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims The aim of the study was to characterize further the role of CYP3A4 in the metabolism of tricyclic antidepressants. Methods The effect of oral ketoconazole (200 mg day(-1) for 14 days) on the kinetics of a single oral dose of imipramine (100 mg) and desipramine (100 mg) was evaluated in two groups of six healthy male subjects. Results Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h(-1) kg(-1) mean +/- s.d.; P<0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P<0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l(-1) h, P<0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected. In the subjects given desipramine, no significant changes in desipramine and 2-hydroxy-desipramine kinetics were observed during ketoconazole treatment. Conclusions These findings indicate that ketoconazole, a relatively specific inhibitor of CYP3A4, inhibits the N-demethylation of imipramine without affecting the 2-hydroxylation of imipramine and desipramine. This interaction, confirms that CYP3A4 plays a role in the demethylation of tricyclic antidepressants.
引用
收藏
页码:315 / 318
页数:4
相关论文
共 28 条
[1]   COMPARATIVE EFFECTS OF THE ANTIMYCOTIC DRUGS KETOCONAZOLE, FLUCONAZOLE, ITRACONAZOLE AND TERBINAFINE ON THE METABOLISM OF CYCLOSPORINE BY HUMAN LIVER-MICROSOMES [J].
BACK, DJ ;
TJIA, JF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (05) :624-626
[2]   IMIPRAMINE DEMETHYLATION AND HYDROXYLATION - IMPACT OF THE SPARTEINE OXIDATION PHENOTYPE [J].
BROSEN, K ;
OTTON, SV ;
GRAM, LF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (05) :543-549
[3]   FLUVOXAMINE IS A POTENT INHIBITOR OF CYTOCHROME-P4501A2 [J].
BROSEN, K ;
SKJELBO, E ;
RASMUSSEN, BB ;
POULSEN, HE ;
LOFT, S .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (06) :1211-1214
[4]   QUINIDINE INHIBITS THE 2-HYDROXYLATION OF IMIPRAMINE AND DESIPRAMINE BUT NOT THE DEMETHYLATION OF IMIPRAMINE [J].
BROSEN, K ;
GRAM, LF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 37 (02) :155-160
[5]  
CHIBA C, 1994, BR J CLIN PHARM, V34, P237
[6]   INVOLVEMENT OF CYP2D6, CYP3A4, AND OTHER CYTOCHROME-P-450 ISOZYMES IN N-DEALKYLATION REACTIONS [J].
COUTTS, RT ;
SU, P ;
BAKER, GB .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1994, 31 (04) :177-186
[7]   THE INFLUENCE OF ENZYME-INDUCTION ON POLYMORPHIC SPARTEINE OXIDATION [J].
EICHELBAUM, M ;
MINESHITA, S ;
OHNHAUS, EE ;
ZEKORN, C .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (01) :49-53
[8]   PHARMACOKINETIC OPTIMIZATION OF TRICYCLIC ANTIDEPRESSANT THERAPY [J].
FURLANUT, M ;
BENETELLO, P ;
SPINA, E .
CLINICAL PHARMACOKINETICS, 1993, 24 (04) :301-318
[9]   FLUCONAZOLE-NORTRIPTYLINE DRUG-INTERACTION [J].
GANNON, RH ;
ANDERSON, ML .
ANNALS OF PHARMACOTHERAPY, 1992, 26 (11) :1456-1457
[10]   THE EFFECTS OF KETOCONAZOLE ON THE INTESTINAL METABOLISM AND BIOAVAILABILITY OF CYCLOSPORINE [J].
GOMEZ, DY ;
WACHER, VJ ;
TOMLANOVICH, SJ ;
HEBERT, MF ;
BENET, LZ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :15-19